Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro

• Published in: Biochimie Vol. 158; pp. 246 - 256
• Main Authors: Focà, Giuseppina, Iaccarino, Emanuela, Focà, Annalia, Sanguigno, Luca, Untiveros, Gustavo, Cuevas-Nunez, Maria, Strizzi, Luigi, Leonardi, Antonio, Ruvo, Menotti, Sandomenico, Annamaria
• Format: Journal Article
• Language: English
• Published: France Elsevier B.V 01.03.2019
• Subjects: Cancer biomarker; Cripto-1; Neutralizing monoclonal antibodies; Cancer biomarker; Neutralizing monoclonal antibodies; Cripto-1
• ISSN: 0300-9084; 1638-6183
• DOI: 10.1016/j.biochi.2019.01.016

Human Cripto-1 (Cripto-1), the founding member of the EGF-CFC superfamily, is a key regulator of many processes during embryonic development and oncogenesis. Cripto-1 is barely present or even absent in normal adult tissues while it is aberrantly re-expressed in various tumors. Blockade of the CFC domain-mediated Cripto-1 functions is acknowledged as a promising therapeutic intervention point to inhibit the tumorigenic activity of the protein. In this work, we report the generation and characterization of murine monoclonal antibodies raised against the synthetic folded CFC [112−150] domain of the human protein. Through subtractive ELISA assays clones were screened for the ability to specifically recognize “hot spot” residues on the CFC domain, which are crucial for the interaction with Activin Type I receptor (ALK4) and GRP78. On selected antibodies, SPR and epitope mapping studies have confirmed their specificity and have revealed that recognition occurs only on a conformational epitope. Furthermore, FACS analyses have confirmed the ability of 1B4 antibody to recognize the membrane-anchored and soluble native Cripto-1 protein in a panel of human cancer cells. Finally, we have evaluated its functional effects through in vitro cellular signaling assays and cell cycle analysis. These findings suggest that the selected anti-CFC mAbs have the potential to neutralize the protein oncogenic activity and may be used as theranostic molecules suitable as tumor homing agents for Cripto-1-overexpressing cancer cells and tissues and to overcome drug-resistance in routine cancer therapies. •New monoclonal antibodies that target Cripto-1 have been developed using the synthetic CFC domain.•Residues involved in antibody recognition have been identified.•The new mAbs bind the folded protein, block ALK4 receptor binding and are useful for protein detection in intact cells.•The new mAbs prevent ERK and c-Src activation in the Cripto-1-overexpressing C8161 melanoma cell line.